Loading asset research
Q3 2026 earnings · Nov 9
Nkarta Inc. Common Stock
NKTXNasdaq · USD · StocksQuote as of · Exchange session not verified$2.85
+3.26%
Today
NKTX
Loading 1D prices…
Market cap
$198M
Volume
933.8K
52w high
$3.7252w low
$1.70Company profile
Nkarta Inc. Common Stock
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
South San Francisco, CA, United States
Employees
106
Fiscal year end
1231
CIK
1787400
Session & valuation
Open$2.72
Previous close$2.76
Day high$2.89
Day low$2.59
30-day avg. volume583.6K
Outstanding shares71.6M
Diluted EPS-$1.41
Latest annual period
P/E (trailing)-2.02
P/E (forward)-1.58
Price / book0.80
Beta0.97
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| SLGLSol-Gel Technologies Ltd. Ordinary Shares | $198.9M | $19.4M | -31.60% | -$2.19 | +1.73% | Buy |
| ORMPOramed Pharmaceuticals Inc. Common Stock | $198.9M | $2M | +3.77% | $1.50 | +1.48% | Hold |
| ADAGAdagene Inc. American Depositary Shares | $202.1M | $7.7M | -229.56% | -$0.30 | +0.34% | Buy |
| VRXAVeraxa Biotech AG Ordinary Shares | $202.2M | — | — | -$0.1989 | +1.44% | Unrated |
| MSLESatellos Bioscience Inc. Common Stock | $186.2M | $0.00 | — | -$1.70 | +3.57% | Buy |